RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to beat back tough blood cancers
Disease control Recruiting nowThis study tests a mix of six chemotherapy drugs in people whose acute lymphoblastic leukemia, lymphoblastic lymphoma, or related blood cancers have returned or stopped responding to treatment. The goal is to see if this combination can shrink or control the cancer and to check f…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
Engineered immune cells target tough childhood leukemia
Disease control Recruiting nowThis early-phase study tests a new type of cell therapy (CAR T cells) that targets two markers on leukemia cells (CD19 and CD22) in children and young adults up to age 21 whose leukemia has returned or not responded to standard treatments. The main goal is to find a safe dose and…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
New combo tackles resistant leukemia in phase 2 trial
Disease control Recruiting nowThis study tests a combination of two drugs—blinatumomab and ponatinib—along with chemotherapy in adults with a specific type of leukemia (Ph-positive ALL) that has come back or not responded to prior treatment. The goal is to see if this approach can improve response rates and s…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
Engineered immune cells take on relapsed leukemia in new trial
Disease control Recruiting nowThis study tests a treatment called CAR T cell therapy for adults with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has returned or not responded to standard treatments. The therapy involves taking a patient's own immune cells, modifying them in a lab to bett…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 00:48 UTC
-
Radioactive antibody targets leukemia before transplant
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk acute leukemias or myelodysplastic syndrome. The antibody seeks out and delivers radiation to cancer cells while sparing healthy cells. The goal is to find …
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis early-phase trial tests a new type of CAR T-cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to target three cancer marker…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control Recruiting nowThis study tests an oral drug called ONC201 in adults whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has returned or stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink or control the cancer. About 120 pa…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
Radioactive antibody blasts cancer before stem cell rescue in High-Risk leukemia trial
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) followed by a donor stem cell transplant for people with high-risk leukemia or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The antibody targets cancer cells and delivers radiation, then c…
Matched conditions: RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC